Compare Globus Medical Inc. Class A Common Stock (GMED) vs Hims and Hers Health Inc (HIMS) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Hims & Hers Health (HIMS) trades at $29.71, down 3.04% on the day, amid a securities class action lawsuit. Technical indicators show a bullish trend, with support near $29 and resistance at $32. Fundamentally, the company reported $2.35B in 2025 revenue but swung to a net loss of -$142M in 2026, with a negative net margin of -5.51%. Valuation ratios are elevated, with a P/E of 57.14 and EV/EBITDA of 205.86. Analyst consensus is a 'Hold' with a $32.17 price target, while recent news is dominated by legal actions.

The outlook for HIMS is clouded by legal overhangs and profitability challenges despite top-line growth. Investment opportunity hinges on resolving litigation and returning to profitability, but risks include regulatory scrutiny and execution missteps. The stock's high valuation multiples require strong future earnings to justify, making it speculative in the near term.